LON:GENI

GENinCode Share Forecast, Price & News

Add

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 54,271 shs
Average Volume: 71,738 shs
Market Capitalization: £18.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Receive GENI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GENinCode and its competitors with MarketBeat's FREE daily newsletter.

GENI Stock Forecast (MarketRank)

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for GENinCode.

0.0 Community Rank

Outperform Votes
GENinCode has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
GENinCode has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about GENinCode and other stocks. Vote “Outperform” if you believe GENI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GENI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
GENinCode does not currently pay a dividend.
Dividend Growth
GENinCode does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GENinCode insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of GENinCode is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GENinCode is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About GENinCode

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

GENI Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Diagnostics & Research
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:GENI
CUSIP: N/A
CIK: N/A
Web: www.genincode.com
Phone: 44 1865 955 847
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.02
Quick Ratio: 17.83

Sales & Book Value

Annual Sales: £1.15 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 1.33
Book Value: GBX 14.30 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 95,817,000
Free Float: N/A
Market Cap: £18.21 million
Optionable: Optionable
Beta: N/A

GENinCode Frequently Asked Questions

Who are GENinCode's key executives?: GENinCode's management team includes the following people:
Mr. Matthew Heaton Walls, Co-Founder, CEO & Director (Age 58, Pay $259.07k)
Mr. Jordi Puig Gilberte, Co-Founder, COO & Director
Mr. Paul Andrew Peter Foulger, CFO, Company Sec. & Director (Age 52, Pay $126.42k)
Who are some of GENinCode's key competitors?: Some companies that are related to GENinCode include Akumin (AKU), SQI Diagnostics (SQD), Oncimmune (ONC), Yourgene Health (YGEN), Verici Dx (VRCI), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), genedrive (GDR), LED Medical Diagnostics (LMD), Abingdon Health (ABDX), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR) and 3D Signatures (DXD).
View all of GENI's competitors.

What is GENinCode's stock symbol?: GENinCode trades on the London Stock Exchange (LON) under the ticker symbol "GENI."
How do I buy shares of GENinCode?: Shares of GENI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
How much money does GENinCode make?: GENinCode (LON:GENI) has a market capitalization of £0.00 and generates £1.15 million in revenue each year.
How can I contact GENinCode?: The official website for GENinCode is www.genincode.com. The company can be reached via phone at 44 1865 955 847.

This page (LON:GENI) was last updated on 6/29/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources